All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-05-11T10:41:30.000Z

Galinpepimut-S granted FDA orphan drug designation

May 11, 2018
Share:

Bookmark this article

On 9 May 2018, SELLAS Life Sciences (SLS) announced that its therapeutic vaccine, Galinpepimut-S (GPS), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). GPS targets the Wilm’s Tumor-1 (WT-1) protein, a known tumor antigen which, along with an adjuvant, stimulates the immune system to fight back. It has been suggested that this could prove highly beneficial if given in combination with other immunomodulatory drugs.  

The vaccine is currently licensed from the Memorial Sloan Kettering Cancer Center, where the research has been carried out, including a phase II trial in which 19 patients with high-risk disease were immunized with GPS following autologous stem cell transplant (ASCT). A median progression-free survival (PFS) of 23.6 months was reported, an 11-month increase compared to data from a comparative trial with a similar sub-group of high-risk patients. An 88% overall survival (OS) of 18 months was also recorded.

A study to assess the clinical benefit of the vaccine in high-risk patients was conducted by Guenther Koehne and presented at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation earlier this year – see previous MM Hub article.

More about...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox